CONy 2021 and Treatment View overview page

2:26
Alpha-synuclein as a therapeutic target for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
1:32
Searching for therapeutic targets for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
1:46
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
1:00
Future prospects in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
1:10
Upcoming treatments for Parkinson’s disease
Zvezdan Pirtosek • 27 Sep 2021
3:04
Challenges in developing gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
3:57
Approved gene-based therapies for neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
2:21
The evolutionary importance of CGRP
Lawrence Robbins • 23 Sep 2021
13:42
RNA- and DNA- based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
1:56
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world
Piero Barbanti • 27 Sep 2021
3:23
Gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
4:17
Reevaluating the amyloid cascade hypothesis
George Perry • 28 Sep 2021
3:30
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS
Nikolaos Grigoriadis • 20 Sep 2021
2:27
Novel targets for Parkinson’s disease: thinking beyond the status quo
Lars Wojtecki • 28 Sep 2021
3:20
Parkinson’s disease: what’s to come in 2022?
Angelo Antonini • 24 Sep 2021
1:24
The future of Parkinson’s disease treatments
Lars Wojtecki • 28 Sep 2021
The content of VJNeurology is intended for healthcare professionals